Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - warfarin sodium - oral tablet - 3mg

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - warfarin sodium - oral tablet - 1mg

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharmaceutical industries europe b.v. - warfarin sodium - oral tablet - 3mg

Vereinigtes Königreich - Englisch - MHRA (Medicines & Healthcare Products Regulatory Agency)

sun pharma uk ltd - warfarin sodium - oral tablet - 500microgram

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ciprofloxacin lactate -

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

viatris limited - warfarin sodium 1mg - tablet - 1 mg - active: warfarin sodium 1mg excipient: amaranth lactose magnesium stearate maize starch quinoline yellow stearic acid - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, thromboembolism associated with atrial fibrillation, and as an adjunct in the prophylaxis of systemic embolism after myocardial infarction.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

viatris limited - warfarin sodium 2mg - tablet - 2 mg - active: warfarin sodium 2mg excipient: amaranth indigo carmine lactose magnesium stearate maize starch stearic acid - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, thromboembolism associated with atrial fibrillation, and as an adjunct in the prophylaxis of systemic embolism after myocardial infarction.

Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

viatris limited - warfarin sodium 5mg - tablet - 5 mg - active: warfarin sodium 5mg excipient: brilliant blue fcf lactose magnesium stearate maize starch quinoline yellow stearic acid - coumadin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, thromboembolism associated with atrial fibrillation, and as an adjunct in the prophylaxis of systemic embolism after myocardial infarction.

Malta - Englisch - Medicines Authority

demo s.a. pharmaceutical industry 21st km national road athens - lamia 14568 krioneri, greece - ciprofloxacin - solution for infusion - ciprofloxacin 2 mg/ml - antibacterials for systemic use

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: macrogol 4000; hypromellose; colloidal anhydrous silica; magnesium stearate; propylene glycol; microcrystalline cellulose; lactose monohydrate; purified talc; titanium dioxide; croscarmellose sodium - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note: specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression, in adults, of chronic, recurrent urinary tract infection.